Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Takeover Mania is Coming!!! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (28)	7/26/2005 6:13:07 PM
From: keokalani'nui	Respond to of 49

IMCL has the pole position, not doubt. But abgx/amgn has a sound registration strategy (SPAs in monotherapy) and a shrewd commercialization strategy (combined with amgn multi-kinase inhibitor). Is there risk? Oh yeah! Does P-Mab work better or worse than E-Mab? No one knows. If it works at least equally well then cost of goods is an issue, then in that situation I much prefer an investment in abgx over imcl. Thus, I think P-Mab though not a deadly serious threat to E-Mab at the moment, is a sufficient threat to discount IMCL's valuation to some degree. That is all.